Acrivon Therapeutics, Inc.
ACRV- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781174
In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Acrivon Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +18 vs. Q3 2022
- Shares held
- 15.0M
- +15.0M vs. Q3 2022
- Total value
- $170.4M
- +$170.4M vs. Q3 2022
- New holders
- 18
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACRV on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 46 | $38.1M |
| Q1 2026 | 44 | $22.6M |
| Q4 2025 | 48 | $44.9M |
| Q3 2025 | 48 | $31.7M |
| Q2 2025 | 53 | $21.2M |
| Q1 2025 | 63 | $45.7M |
| Q4 2024 | 63 | $140.0M |
| Q3 2024 | 55 | $160.8M |
| Q2 2024 | 55 | $136.1M |
| Q1 2024 | 48 | $109.0M |
| Q4 2023 | 42 | $74.5M |
| Q3 2023 | 43 | $144.3M |
| Q2 2023 | 40 | $196.0M |
| Q1 2023 | 39 | $191.1M |
| Q4 2022 | 18 | $170.4M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Acrivon Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 4,810,508 | $55.4M | 1.12% | +4,810,508 | New |
| Perceptive Advisors LLC | 3,007,858 | $34.7M | 1.00% | +3,007,858 | New |
| Sands Capital Ventures, LLC | 1,652,605 | $19.0M | 5.21% | +1,652,605 | New |
| Citadel Advisors LLC | 1,634,104 | $18.2M | 0.02% | +1,634,104 | New |
| Marshall Wace, LLP | 1,223,252 | $14.1M | 0.04% | +1,223,252 | New |
| Wellington Management Group LLP | 900,149 | $9.99M | 0.00% | +900,149 | New |
| Federated Hermes, Inc. | 823,300 | $9.48M | 0.03% | +823,300 | New |
| NEA Management Company, LLC | 481,677 | $4.44M | 0.25% | +481,677 | New |
| HealthCor Management, L.P. | 284,201 | $3.27M | 3.00% | +284,201 | New |
| Bank of Montreal | 42,444 | $545.0K | 0.00% | +42,444 | New |
| Goldman Sachs Group Inc | 38,800 | $447.0K | 0.00% | +38,800 | New |
| Two Sigma Investments, LP | 21,534 | $248.1K | 0.00% | +21,534 | New |
| Millennium Management LLC | 19,639 | $226.0K | 0.00% | +19,639 | New |
| DAFNA Capital Management LLC | 15,648 | $180.3K | 0.05% | +15,648 | New |
| UBS Group AG | 4,748 | $54.7K | 0.00% | +4,748 | New |
| Barclays PLC | 4,142 | $47.7K | 0.00% | +4,142 | New |
| Morgan Stanley | 869 | $10.0K | 0.00% | +869 | New |
| Tower Research Capital LLC (TRC) | 159 | $2.00K | 0.00% | +159 | New |